All News

MRD testing transforms multiple myeloma treatment, guiding personalized strategies and improving patient outcomes through innovative testing methods.

Kausik K. Ray, MD, discussed the importance of early, aggressive, and sustained LDL-C lowering for atherosclerotic cardiovascular disease prevention, highlighting that the magnitude of cardiovascular risk reduction is independent of the specific lipid-lowering therapy used.

Børge G. Nordestgaard, MD, DMSc, discussed the role of remnant cholesterol as an independent risk factor for atherosclerotic cardiovascular disease and the emerging therapies that may help manage residual cardiovascular risk beyond low-density lipoprotein cholesterol reduction.

Incretin-based therapies, including GLP-1 and dual GLP-1/GIP receptor agonists, are transforming the management of type 2 diabetes, obesity, and cardiovascular risk.

Frank Qian, MD, MPH, discusses clinical considerations for omega-3 fatty acid therapy, such as the patient populations who may benefit most and important safety concerns.

Frank Qian, MD, MPH, discusses the clinical indications, dosing strategies, and cardiovascular outcomes data for prescription omega-3 fatty acids, including the ongoing debate about EPA vs EPA-DHA formulations and the implications of recent trial findings.

Explore how the gut microbiome influences cancer therapy responses, resistance mechanisms, and the potential of microbiota-focused strategies for improved outcomes.

GLP-1 receptor agonists, including semaglutide and tirzepatide, significantly reduce cardiometabolic risk factors such as dyslipidemia, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, obstructive sleep apnea, chronic kidney disease, and cardiovascular events, with evidence suggesting that some of these benefits may occur independently of weight loss.

Gurjyot K. Doshi, MD, discusses key updates to medically integrated pharmacy standards, which reflect the evolving landscape of oral oncolytic therapy.

IVIG treatment significantly boosts platelet counts in pregnant people with thrombocytopenia, revealing key predictors for effective response and optimizing clinical decisions.

Emerging therapies targeting apolipoprotein C-III (ApoC3) are demonstrating significant promise in lowering triglycerides and reducing cardiovascular risk for patients with severe hypertriglyceridemia and rare disorders, such as familial chylomicronemia syndrome.

Groundbreaking oncology drugs transform treatment for glioblastoma, HR+ breast cancer, and small cell lung cancer.

Building on positive low-density lipoprotein cholesterol (LDL-C)-lowering seen in patients with atherosclerotic cardiovascular disease, inclisiran was found to induce meaningful and sustained LDL-C reductions following recent acute coronary syndrome.

Enhanced dermatologic management reduces skin rash and improves quality of life for patients with EGFR-mutant non-small cell lung cancer.

A study of early-onset colorectal cancer found significant racial disparities, with younger patients more frequently diagnosed at advanced stages.

The FDA grants fast track designation to TEV-53408, a promising treatment for celiac disease designed to address gluten intolerance and improve patient outcomes.

The announcement is set to affect multiple grants awarded to Moderna, which is developing mRNA-1018, a candidate vaccine against avian influenza.

Zongertinib shows significant benefits in managing symptoms and improving quality of life for patients with HER2-mutated non-small cell lung cancer.

Sander Kersten, PhD, discusses the distinct roles of ANGPTL3 and ANGPTL4 in lipid metabolism, their interactions with key enzymes, the therapeutic potential of targeting these pathways in lipid-lowering strategies, and important considerations for pharmacists counseling patients on emerging ANGPTL-targeted therapies.

Katherine H. Saunders, MD, DABOM, explores the role of pharmacists in supporting long-term weight management with GLP-1 therapies, including strategies for counseling on lifestyle interventions, managing adverse effects, and ensuring patients receive individualized, evidence-based care.

Researchers explore cellular senescence's role in kidney fibrosis, highlighting potential therapies to combat chronic kidney disease progression.

The test offers health care professionals a simple and efficient method of identifying patients with liver fibrosis of varying severity.

Shore Medical Center enhances patient safety with a pharmacy-driven intravenous to oral opioid conversion protocol, minimizing risks and improving pain management.

The pharmacy is proud to be community focused and patient centered.

CKD is a complication of diabetes. Emerging treatments aim to optimize management and reduce risks. Pharmacists are key in applying new evidence to clinical practice.

Two abstracts from the American Society of Clinical Oncology (ASCO) annual meeting demonstrate that pretreatment DPYD genotyping improves the safety and cost-effectiveness of fluoropyrimidine chemotherapy, with oncology pharmacists playing a pivotal role in implementing and optimizing genotype-guided dosing strategies.